The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
47 is a good offer at reasonable split of 21:26. Just wanna see price over 45 so i sell it n move on :-)
Based on the 3rd rejected offer, the Shire BOD said �46.50/share was a price they unanimously agreed was an offer that significantly undervalued the company�s value/growth/pipeline...importantly they didn�t say the price was in the ball park but they wanted more cash than paper. That was the press. So they now offer an extra �0.50 per share!!! Very strange offer imho...ATB, Scfc
47 is a good offer at reasonable split of 21:26. ust wanna see price over 45 so i sell it move on :-)
Thank you. May we all be big winners in this no losers. Fingers crossed hey?
Latest rns says they can they are now offering 47 pounds.
Thats my exact feelings . Cant see the offer being accepted.
I still believe shire is worth in the region of £47-£50 per share. Don’t think the Japanese can stretch to this. So maybe a bigger player is waiting to put an offer in when the price seems right to them. But Shire should carry on business as per usual till the right offer is in the table.
A whole 50 pence increased offer (split with �21 cash) - seriously? Scfc
£21 cash reported , getting my info from bloom
Share price on the move heading for �39
Bid upped to 47
Still dont see any deal with takeda being agreed but they seem to be hell bent on pushing it through. Ill still be surprised though if another contender doesnt appear - imo
Reuters: Takeda to raise bid to over 47 pounds.
Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T> is considering raising its cash-and-stock bid for London-listed drug maker Shire Plc (SHP.L) to approximately 47 pounds per share or more, people familiar with the matter said on Friday. Takeda is still finalising its latest offer, the sources said, asking not to be identified because the deliberations are confidential. On Thursday, the companies disclosed that Shire had rejected Takeda's third indicative bid of 46.50 pounds per share. Takeda and Shire did not immediately respond to requests for comment.
I expect a formal announcement Monday from Takeda. I hope!
Lol.....:-)))) Good one!
its a fact : since WWII Japs don't do hostile bids
Bloomberg piece: https://www.bloomberg.com/news/articles/2018-04-20/shire-rebuff-may-not-dim-takeda-s-appetite-for-60-billion-deal
Sry that should read: Shire rebuff may NOT dim Takeda's appetite for a takover!
Here is what Bloomsburg is saying: Shire rebuff may dim Takeda's appetite for a takover! Weber�s pursuit of the mammoth acquisition reveals the challenge he faces in ensuring the future of Japan�s biggest drugmaker. With few late-stage experimental drugs in its own pipeline and a shrinking home market, Takeda needs lucrative new therapies like Shire�s medicines for rare diseases. That could drive Weber to keep pushing for a deal even as questions swirl about his ability to pull off such a big purchase. A group of Japanese lenders, including Sumitomo Mitsui Financial Group Inc. and Mitsubishi UFJ Financial Group Inc., have agreed to arrange 1 trillion yen ($9.3 billion) in financing for the deal, according to a person familiar with the matter.The financing total may still change as Takeda�s discussions with Shire progress, according to the person, who asked not to be identified as the information is not public. Sumitomo Mitsui did not immediately respond to a request for comment on the financing arrangement. An MUFG spokesman declined to comment. There�s a good chance Takeda could come back with another offer, and in order to make it more appealing to Shire shareholders it may have to boost the cash portion of its bid, said Credit Suisse Group analyst Fumiyoshi Sakai.
Evening Standard lunchtime report - Shire dives as takeover by Japan's Takeda looks dead in the water
Hope there will be some positive rumours over the weekend of takeda improving cash to equity ratio and a new bidder emerging:-))
Shares in Shire were on the slide on Friday as the chatter on the trading floors was that a takeover of the pharmaceuticals giant is now doomed. Shire said yesterday afternoon that it had rejected three offers from Takeda of Japan, and that triggered the revelation that US firm Allergan had also taken a look but decided against making an offer. Shire says it wants to keep talking but traders believe enough is enough, and Takeda would struggle to put together a bigger offer. The Japanese company is smaller than Shire and was already stretched when it made its third offer � worth �44 billion, or �46.50 a share. Takeda�s shares slipped 5% overnight in Tokyo as shareholders doubted if the firm could afford it. Shire today lost 149p at 3826p.
I believe that shire is definitely a takeover target but not for now, therefore in the short-term i see a pullback to ~33-35 with sideways trading until something else emerges. Just my opinion.
Where-is-my, not sure what screen you look at but there hasn�t been a big drop (other than at open of course) - lowest trade price to date is 3764p. ATB, Scfc